World premiere | Announcing Sanyou Super-Trillion Innovative Antibody Discovery Platform

Sanyou Biopharmaceuticals officially launched STAL (Super-Trillion Antibody Libraries) on May 28, 2022, which is an innovative Sanyou intellectual property super-trillion antibody drug discovery platform.

Developed by Sanyou after seven years of continuous innovation and independent R&D, STAL represents a revolutionary breakthrough from the previous generation of the innovative trillion antibody discovery platforms. The STAL Discovery Platform integrates nine categories of innovative super-trillion antibody libraries with an overall library capacity of up to 10 trillion. Screening validations with dozens of targets have shown that thousands of novel antibodies can be discovered through the STAL platform, and the quantity is tens or even hundreds of times greater than that of canonical methods.

Hundreds of millions of patients around the world suffer from cancers, autoimmune diseases, allergic diseases and metabolic diseases every year. Drugs, including monoclonal antibodies, bispecific antibodies, ADC, AOC, RAC, PDC, and CAR-T therapy, are the main treatments for these diseases. More than 100 biologic drugs have been approved with total annual market revenues approaching $200 billion. High specificity antibodies are the common building blocks of these drugs and play an important role in precise targeting.

The STAL discovery platform integrates phage display and mammalian cell expression technologies, and is complemented by fully automated screening and integrated antibody drug R&D platforms. STAL is effective in challenging innovative targets and developing very difficult drug modalities. It can meet R&D needs related to the discovery of various innovative biological drugs, including fully human antibodies, humanized single domain antibodies, humanized monoclonal antibodies, bispecific antibodies, multispecific antibodies, polypeptides, ADCs, PDC and miniaturized proteins. The candidates obtained have natural conformations, a high affinity and a great capacity for development.

The STAL discovery platform is based on a customer-oriented, modular, diversified and personalized commercial system, which is applicable not only to the R&D of various innovative biological drugs, but also to the research of disease mechanisms and the development of diagnostic. Dozens of projects from the platform have delivered preclinical candidates, several projects have completed preclinical R&D and entered the clinical phase.

Dr. Guojun Lang, CEO of Sanyou, said, “Innovative drug research and development has gradually entered a difficult era where we have to overcome very difficult innovative targets, new drug modalities and diseases of a complex intriguing”.

“The STAL Discovery Platform comprises nine super-trillion antibody libraries, with up to hundreds of times the number of lead antibodies compared to canonical antibody discovery technologies. The platform integrates technologies for generating a variety of biological drugs such as fully human antibodies, humanized antibodies, miniaturized nanobodies, affinity polypeptides and affinity miniaturized proteins, so that it is suitable not only to the development of antibodies targeting conventional epitopes, but also to the development of antibodies targeting specific epitopes and refined epitopes. Furthermore, the platform seamlessly integrates phage display technology and mammalian cell expression technology, so that it is not only suitable for cross-screening with proteins from different species such as humans, mice and monkeys, but also for the positive/negative screening of differentiated proteins such as mutation sites, competing antibodies, Fc fusion proteins and His fusion proteins, as well as for the complex screening of difficult targets such as cellular antigens, polypeptide antigens and transmembrane antigens.

“The STAL discovery platform has been integrated in a modular way with the integrated preclinical platform for research and development on innovative antibodies. As a result, various antibody discovery services, featured technical services, and staged technical services can be implemented flexibly, and the discovery of preclinical candidates and the integrated R&D of preclinical biologic drugs can be carried out as single solution. Based on this platform, Sanyou is also developing an intelligent and innovative antibody-based drug discovery platform. »

“It is believed that Sanyou’s integrated preclinical innovative antibody R&D platform, STAL discovery platform and intelligent innovative antibody drug discovery platform will prominently help our partners lead the competition. , to overcome the difficulties of drug innovations and to develop more of them. high quality innovative medicines for the benefit of patients.

About Sanyou Biopharmaceuticals

Sanyou Biopharmaceuticals Co., Ltd. is a world-renowned biotechnology and high-tech company that focuses on the R&D and services of innovative antibody drugs.

Sanyou is committed to establishing a high-quality, high-throughput and leading integrated R&D and value transformation platform for innovative antibodies, building a commercial ecosystem including therapy, R&D products and services and diagnostics, and to cooperate with biopharmaceutical, diagnostic, and pharmaceutical R&D companies to make new advances in the diagnosis and treatment of human disease.

Sanyou has set up an innovative antibody research and development integrated laboratory of several thousand square meters with state-of-the-art facilities. There are 10 major functional modules and more than 40 core technology platforms, which are featured by a series of Super-Trillion phage display antibody libraries and integrated platforms covering innovative antibody drug discovery, innovative optimization of antibody drugs, construction of production cell lines, upstream and downstream process development, preclinical R&D and industrial development, etc.

Sanyou has built a business system that integrates “differentiated CRO, innovative CPO and characteristic CRS”, and constantly launches new technologies, new products, new services and new scenarios based on the principle of high quality, fast delivery and profitability. Friendly business collaborations have been established with more than 300 pharmaceutical companies, drug research and development institutes and diagnostic companies all over the world.

Media Contact
Company Name: Sanyou Biopharmaceuticals (Shanghai) Co., Ltd.
Contact person: Guohong He
E-mail: Send an email
Call: +1-669252 9564
Address:3/F, Building 6, No. 188 Xinjunhuan Road, Minhang District
Town: Shanghai 201114
Country: China
Website: www.sanyoubio.com

Comments are closed.